Puma Biotechnology (PBYI) Given Daily Media Impact Rating of 0.20

Share on StockTwits

Press coverage about Puma Biotechnology (NASDAQ:PBYI) has trended somewhat positive this week, according to Accern Sentiment. The research firm identifies negative and positive news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Puma Biotechnology earned a news sentiment score of 0.20 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 47.3809291303018 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

These are some of the media stories that may have effected Accern Sentiment Analysis’s scoring:

NASDAQ PBYI opened at $47.30 on Friday. The stock has a market capitalization of $1.72 billion, a P/E ratio of -6.03 and a beta of -0.22. Puma Biotechnology has a twelve month low of $40.45 and a twelve month high of $136.90. The company has a current ratio of 2.68, a quick ratio of 2.64 and a debt-to-equity ratio of 3.14.

Puma Biotechnology (NASDAQ:PBYI) last posted its earnings results on Thursday, August 9th. The biopharmaceutical company reported ($1.17) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.26) by $0.09. The business had revenue of $50.80 million for the quarter, compared to analysts’ expectations of $45.67 million. Puma Biotechnology had a negative net margin of 146.27% and a negative return on equity of 367.92%. During the same quarter in the previous year, the firm posted ($1.38) earnings per share. research analysts anticipate that Puma Biotechnology will post -3.86 earnings per share for the current fiscal year.

A number of brokerages have recently commented on PBYI. ValuEngine lowered shares of Puma Biotechnology from a “sell” rating to a “strong sell” rating in a research report on Tuesday, May 22nd. Cowen reaffirmed a “hold” rating and set a $80.00 price objective on shares of Puma Biotechnology in a research report on Friday, August 10th. BidaskClub raised shares of Puma Biotechnology from a “hold” rating to a “buy” rating in a research report on Wednesday, June 20th. Stifel Nicolaus cut their price objective on shares of Puma Biotechnology from $95.00 to $87.00 and set a “buy” rating for the company in a research report on Friday, May 11th. Finally, Citigroup upped their price objective on shares of Puma Biotechnology from $146.00 to $164.00 and gave the company a “buy” rating in a research report on Thursday, June 28th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and six have issued a buy rating to the stock. Puma Biotechnology has an average rating of “Hold” and an average price target of $101.40.

In other Puma Biotechnology news, insider Richard Paul Bryce sold 1,836 shares of the company’s stock in a transaction dated Friday, July 20th. The shares were sold at an average price of $51.95, for a total transaction of $95,380.20. Following the sale, the insider now directly owns 32,543 shares of the company’s stock, valued at $1,690,608.85. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Alan H. Auerbach sold 12,520 shares of the company’s stock in a transaction dated Friday, July 20th. The stock was sold at an average price of $52.00, for a total transaction of $651,040.00. Following the sale, the chief executive officer now directly owns 4,179,061 shares in the company, valued at $217,311,172. The disclosure for this sale can be found here. Insiders own 21.50% of the company’s stock.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous)).

Recommended Story: What are the Benefits of Index Funds?

Insider Buying and Selling by Quarter for Puma Biotechnology (NASDAQ:PBYI)

Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply